NextCell Pharma AB (OSTO:NXTCL) Tariff Resilience Score: 0/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NXTCL NextCell Pharma AB OSTO:NXTCL
42 GF Score
Price kr1.13
GF Value kr0.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Tariff Resilience Score?

NextCell Pharma AB has the Tariff Resilience Score of 0, which implies that the company might have .

NextCell Pharma AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes NextCell Pharma AB might have .

NextCell Pharma AB  (OSTO:NXTCL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

NextCell Pharma AB Tariff Resilience Score Related Terms

OSTO:NXTCL
42GF Score
NextCell Pharma AB OSTO:NXTCL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of kr1.13 is trading 25.1% above its estimated GF Value™ of kr0.90. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for OSTO:NXTCL:

  • Tariff Resilience Score: 0
  • GF Value™: kr0.90 vs. price of kr1.13 (25.1% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NextCell Pharma AB Business Description

Other Exchanges 65G:Germany
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for OSTO:NXTCL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.13
Price
kr0.90
GF Value